Logo image of EDSA

EDESA BIOTECH INC (EDSA) Stock Fundamental Analysis

NASDAQ:EDSA - Nasdaq - CA27966L3065 - Common Stock - Currency: USD

2.36  +0.01 (+0.43%)

Fundamental Rating

2

EDSA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While EDSA seems to be doing ok healthwise, there are quite some concerns on its profitability. EDSA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year EDSA has reported negative net income.
EDSA had a negative operating cash flow in the past year.
EDSA had negative earnings in each of the past 5 years.
EDSA had a negative operating cash flow in each of the past 5 years.
EDSA Yearly Net Income VS EBIT VS OCF VS FCFEDSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

EDSA's Return On Assets of -146.70% is on the low side compared to the rest of the industry. EDSA is outperformed by 84.68% of its industry peers.
EDSA's Return On Equity of -269.83% is on the low side compared to the rest of the industry. EDSA is outperformed by 73.59% of its industry peers.
Industry RankSector Rank
ROA -146.7%
ROE -269.83%
ROIC N/A
ROA(3y)-112.41%
ROA(5y)-88.99%
ROE(3y)-135.95%
ROE(5y)-106.1%
ROIC(3y)N/A
ROIC(5y)N/A
EDSA Yearly ROA, ROE, ROICEDSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

EDSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EDSA Yearly Profit, Operating, Gross MarginsEDSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for EDSA has been increased compared to 1 year ago.
The number of shares outstanding for EDSA has been increased compared to 5 years ago.
EDSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EDSA Yearly Shares OutstandingEDSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EDSA Yearly Total Debt VS Total AssetsEDSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

2.2 Solvency

EDSA has an Altman-Z score of -20.58. This is a bad value and indicates that EDSA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -20.58, EDSA is doing worse than 86.27% of the companies in the same industry.
There is no outstanding debt for EDSA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.58
ROIC/WACCN/A
WACCN/A
EDSA Yearly LT Debt VS Equity VS FCFEDSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

EDSA has a Current Ratio of 1.09. This is a normal value and indicates that EDSA is financially healthy and should not expect problems in meeting its short term obligations.
EDSA's Current ratio of 1.09 is on the low side compared to the rest of the industry. EDSA is outperformed by 87.50% of its industry peers.
EDSA has a Quick Ratio of 1.09. This is a normal value and indicates that EDSA is financially healthy and should not expect problems in meeting its short term obligations.
EDSA has a worse Quick ratio (1.09) than 85.74% of its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
EDSA Yearly Current Assets VS Current LiabilitesEDSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

EDSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.22%, which is quite impressive.
EPS 1Y (TTM)30.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EDSA will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.62% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.05%
EPS Next 2Y24.78%
EPS Next 3Y21.93%
EPS Next 5Y16.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EDSA Yearly Revenue VS EstimatesEDSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 200K 400K 600K 800K 1M
EDSA Yearly EPS VS EstimatesEDSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15 -20 -25

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EDSA. In the last year negative earnings were reported.
Also next year EDSA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EDSA Price Earnings VS Forward Price EarningsEDSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EDSA Per share dataEDSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as EDSA's earnings are expected to grow with 21.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.78%
EPS Next 3Y21.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EDSA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDESA BIOTECH INC

NASDAQ:EDSA (4/25/2025, 8:02:54 PM)

2.36

+0.01 (+0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-14 2025-02-14/amc
Earnings (Next)05-08 2025-05-08
Inst Owners6.38%
Inst Owner Change0%
Ins Owners7.98%
Ins Owner Change18.23%
Market Cap16.57M
Analysts82.86
Price Target19.38 (721.19%)
Short Float %1.22%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.23%
Min EPS beat(2)-51.8%
Max EPS beat(2)47.35%
EPS beat(4)3
Avg EPS beat(4)6.41%
Min EPS beat(4)-51.8%
Max EPS beat(4)47.35%
EPS beat(8)7
Avg EPS beat(8)21.78%
EPS beat(12)11
Avg EPS beat(12)27.46%
EPS beat(16)13
Avg EPS beat(16)12.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.32%
PT rev (3m)-7.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.32
P/tB 78.74
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-1.35
Fwd EYN/A
FCF(TTM)-0.71
FCFYN/A
OCF(TTM)-0.71
OCFYN/A
SpS0
BVpS0.32
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -146.7%
ROE -269.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-112.41%
ROA(5y)-88.99%
ROE(3y)-135.95%
ROE(5y)-106.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z -20.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)5.56%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y13.05%
EPS Next 2Y24.78%
EPS Next 3Y21.93%
EPS Next 5Y16.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y63.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.92%
OCF growth 3YN/A
OCF growth 5YN/A